Curtis Ruegg, Ph.D.
CEO & President
During more than 25 years in the biopharmaceutical industry, Curtis has built and managed several successful novel biologics development programs, from research through clinical development and resulting in health authority approval and commercialization. Prior to joining Amphivena, Curtis was President and CEO at Parvus Therapeutics developing a novel biologics platform targeting regulatory T cells for the treatment of autoimmune disease. Prior to Parvus, Curtis was Executive Vice President, Technical Operations at Revance where he established and managed the biologics development program to support the Company’s first IND spanning through Phase 3. Prior to Revance, Curtis led development efforts supporting commercialization of several products including Ventavis® (CoTherix), Esbriet® (Intermune) and Provenge® (Dendreon). Curtis earned his Ph.D. degree from Johns Hopkins University School of Medicine for research on retroviral mediated immunosuppression and performed research in immunology as a Cancer Research Institute Fellow at Stanford University School of Medicine.